[1] |
CAO Fei, YU Wenhao, TANG Xiaonan, MA Zidong, CHANG Tingmin, GONG Yabin, LIAO Mingjuan, KANG Xiaohong.
Mechanism of LINC01410 promoting proliferation and migration in esophageal squamous cell carcinoma
[J]. China Oncology, 2024, 34(8): 753-762.
|
[2] |
LIAO Ziyi, PENG Yang, ZENG Beilei, MA Yingying, ZENG Li, GAN Kelun, MA Daiyuan.
Analysis of pathological remission degree and influencing factors of radical surgery after neoadjuvant immunotherapy combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
[J]. China Oncology, 2024, 34(7): 669-679.
|
[3] |
WANG Shanshan, YE Dingwei, YANG Li, CHENG Fan, YANG Tiejun, ZHANG Xiaoping, YU Zhixian, ZHANG Qingyun, YANG Yong.
Correlation of HER2 expression and clinicopathological characteristics in patients with urothelial carcinoma in China
[J]. China Oncology, 2024, 34(11): 1011-1019.
|
[4] |
WU Zhibai, XU Guiqin, ZHANG Li, YANG Zhaojuan, LIU Yun, JIAO Kun, CHEN Zehong, XU Chen, ZUO You, ZHENG Ningqian, YE Zhiqian, LIU Yongzhong.
Mechanism study of KCMF1 promoting proliferation and NF-κB signaling transduction in colorectal cancer cells
[J]. China Oncology, 2024, 34(11): 987-997.
|
[5] |
ZHAO Junxiu, ZHU Yi, SONG Xiaoyu, ZHE Chao, XIAO Yuhan, LIU Yunduo, LI Linhai, XIAO Bin.
Circ-0007766 acts as a miR-1972 sponge to promote breast cancer cell migration and invasion via upregulation of HER2
[J]. China Oncology, 2024, 34(10): 915-930.
|
[6] |
TAN Xiaolang, YAO Sha, WANG Guihua, PENG Luogen.
Research on uPAR promoting proliferation, migration, and chemoresistance of pancreatic cancer by inhibiting autophagy via MAPK signaling
[J]. China Oncology, 2024, 34(10): 944-956.
|
[7] |
KANG Yinnan, CHEN Shun, XIE Youcheng, ZHENG Ying, HE Yujing, LI Chuyi, YU Xiaohui.
Application and research progress of antibody drug conjugates in HER2 positive advanced gastric cancer
[J]. China Oncology, 2023, 33(8): 790-800.
|
[8] |
ZHOU Cong, HE Lina, CHENG Xiaojiao, HUANG Tinglei, TU Shuiping.
Effect of RSPO3 on inhibiting the growth of colorectal cancer transplanted tumors and increasing NK cell infiltration in vivo
[J]. China Oncology, 2023, 33(7): 664-672.
|
[9] |
WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng.
Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study
[J]. China Oncology, 2023, 33(7): 686-692.
|
[10] |
CHEN Lijun, WANG Yichen, ZHENG Qiang, WANG Yue, JIN Yan, LI Yuan.
Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma
[J]. China Oncology, 2023, 33(5): 469-477.
|
[11] |
YANG Wenxiao, GUO Linwei, LING Hong, HU Xin.
Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy
[J]. China Oncology, 2023, 33(5): 484-498.
|
[12] |
CHEN Hong, CHEN Junxia.
Effect of hsa_circ_0001573 on biological behaviors of breast cancer cells and its molecular mechanism
[J]. China Oncology, 2023, 33(4): 342-353.
|
[13] |
LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun.
The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy
[J]. China Oncology, 2023, 33(4): 377-387.
|
[14] |
SHAO Zhibo, YANG Benlong, WU Jiong.
Progress of important clinical trials of breast cancer in China in 2022
[J]. China Oncology, 2023, 33(2): 103-109.
|
[15] |
LENG Jie, QIU Guochun, ZHANG Bo, PU Yan.
Mechanism of breast cancer centrosome regulatory protein SEC23B on tumor invasion and metastasis
[J]. China Oncology, 2023, 33(2): 152-161.
|